Dr. Ton N. Schumacher is the deputy director of the Netherlands Cancer Institute in Amsterdam and a professor of Immunotechnology at Leiden University Medical Center.
Dr. Schumacher is renowned for advancing our understanding of how immune cells identify tumor-specific antigens and then use them to target cancer cells, and for his development of techniques that improved our ability to identify and monitor anti-cancer T cell responses before and after treatment. Among other honors, he has received the 2016 William B. Coley Award for Distinguished Research in Tumor Immunology and was elected to the European Molecular Biology Organization (EMBO).
In addition to serving on CRI’s Scientific Advisory Council, Dr. Schumacher is a member of CRI’s Clinical Leadership Committee, the CRI-SU2C Dream Team, and is involved in CRI’s partnership with the Parker Institute for Cancer Immunotherapy, which seeks to develop personalized anti-cancer vaccines.
In a way, our findings show that the immune response in cancer patients can be strengthened; there is more on the cancer cells that makes them foreign that we can exploit.
¡Hagamos correr la voz sobre la inmunoterapia! Haga clic para compartir esta página con su comunidad.